Edwards Lifesciences introduced TAVR to the U.S. back in November 2011 when FDA approved its Sapien heart valve for patients with aortic stenosis who were too sick to undergo open heart surgery. This episode of Pivot features Larry Wood, corporate vice president for TAVR with Edwards, who reflects on the journey.
This year, more than 5 million Americans will be diagnosed with Heart Valve Disease. All too often, for Black patients with certain forms of the disease this can be a death sentence, with patients from minority communities facing significantly higher mortality rates than their white counterparts. The most common form of this disease is aortic […]
Employees who enjoy their benefits are more inclined to stay with their company. A 2025 Marsh McLennan Agency report said 73% of employees would remain if plan options were better.
Minimally-invasive treatment options like transcatheter aortic valve replacement (TAVR) could be a good option for some patients because patients typically stay in the hospital for shorter periods of time.
Boston Scientific has traditionally come in third in the TAVR marketplace behind Medtronic and Edwards Lifesciences but CEO Michael Mahoney talked about how it plans to change that at the Medtech Conference in Minneapolis last week.
Boston Scientific may have purchased Swiss structural heart company Symetis for many reasons but one could very well be that the Lotus aortic valve is not ready for prime time.
The Food and Drug Administration expands the indication for Edwards Lifesciences' Sapien 3 valve allowing the transcatheter aortic valve replacement procedure to aortic stenosis patients who have intermediate risk of undergoing open-heart surgery.
The layout of your phlebotomy station can significantly impact efficiency. A well-thought-out setup ensures that every tool is within reach, minimizing unnecessary movement and reducing patient wait times.